Sarepta Therapeutics (SRPT) : Sarepta Therapeutics (SRPT) had a healthy money flow of $1.56 million into the stock during the Thursdays trading session. The value of bullish trades on upticks was $6.83 million, whereas, investors only sold shares worth $5.28 million on downticks. The stock closed the day with an up-down ratio of 1.3.The money flow in the block trades to the tune of $1.12 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $1.36 million worth of transactions were on upticks. A paltry $0.24 million worth of block trade transactions on downticks shows that the investors are reluctant to sell the stock down. The total up-down ratio of the upticks vs the downticks in block trades was 5.73. Sarepta Therapeutics (SRPT) stock slid $0.14 intraday and traded at 20.75, a change of -0.67% over previous days close. However, for the week, the company shares are 2.47% compared to previous weeks close.
Sarepta Therapeutics (SRPT) : Currently there are 12 street experts covering Sarepta Therapeutics (SRPT) stock. The most bullish and bearish price target for the stock is $60 and $4 respectively for the short term. The average price target of all the analysts comes to $21.92. The estimated standard deviation from the target is $16.39. The stock has recorded a 20-day Moving Average of 11.55% and the 50-Day Moving Average is 16.2%.
Sarepta Therapeutics (NASDAQ:SRPT): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $20.94 and $20.45 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $21.20. The buying momentum continued till the end and the stock did not give up its gains. It closed at $20.92, notching a gain of 0.14% for the day. The total traded volume was 3,268,641 . The stock had closed at $20.89 on the previous day.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.